

NAJWAŻNIEJSZE PUBLIKACJE z 2019

Kliniki Chorób Zakaźnych i Hepatologii UMB

- 1: Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, Manns M, Kaita K, Krastev Z, Lee SS, Cathcart AL, Crans G, Op den Brouw M, Jump B, Gaggar A, Flaherty J, Buti M. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. *Liver Int.* 2019 Oct;39(10):1868-1875. doi: 10.1111/liv.14155. Epub 2019 Jul 10. PMID: 31136052.
- 2: Brouwer WP, Chan HLY, Lampertico P, Hou J, Tangkijvanich P, Reesink HW, Zhang W, Mangia A, Tanwandee T, Montalto G, Simon K, Ormeci N, Chen L, Tabak F, Gunsar F, Flisiak R, Ferenci P, Akdogan M, Akyuz F, Hirankarn N, Jansen L, Wong VW, Soffredini R, Liang X, Chen S, Groothuisink ZMA, Santoro R, Jaroszewicz J, Ozaras R, Kozbial K, Brahmania M, Xie Q, Chotiayaputta W, Xun Q, Pazgan-Simon M, Oztas E, Verhey E, Montanari NR, Sun J, Hansen BE, Boonstra A, Janssen HLA; GIANT-B Global Consortium. Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. *Clin Infect Dis.* 2019 Nov 13;69(11):1969-1979. doi: 10.1093/cid/ciz084. PMID: 30715261; PMCID: PMC6853659.
- 3: Pawłowska M, Flisiak R, Gil L, Horban A, Hus I, Jaroszewicz J, Lech-Marańda E, Styczyński J. Prophylaxis of hepatitis B virus (HBV) infection reactivation - recommendations of the Working Group for prevention of HBV reactivation. *Clin Exp Hepatol.* 2019 Sep;5(3):195-202. doi: 10.5114/ceh.2019.87631. Epub 2019 Sep 5. PMID: 31598555; PMCID: PMC6781818.
- 4: Świdarska M, Maciejczyk M, Zalewska A, Pogorzelska J, Flisiak R, Chabowski A. Oxidative stress biomarkers in the serum and plasma of patients with non-alcoholic fatty liver disease (NAFLD). Can plasma AGE be a marker of NAFLD? Oxidative stress biomarkers in NAFLD patients. *Free Radic Res.* 2019 Aug;53(8):841-850. doi: 10.1080/10715762.2019.1635691. Epub 2019 Jul 8. PMID: 31234658.
- 5: Buti M, Wong DK, Gane E, Flisiak R, Manns M, Kaita K, Janssen HLA, Op den Brouw M, Jump B, Kitrinis K, Crans G, Flaherty J, Gaggar A, Marcellin P. Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. *Lancet Gastroenterol Hepatol.* 2019 Apr;4(4):296-304. doi: 10.1016/S2468-1253(19)30015-9. Epub 2019 Feb 20. PMID: 30795958.
- 6: Amele S, Peters L, Sluzhynska M, Yakovlev A, Scherrer A, Domingo P, Gerstoft J, Viard JP, Gisinger M, Flisiak R, Bhaghani S, Ristola M, Leen C, Jablonowska E, Wandeler G, Stellbrink H, Falconer K, D'Arminio Monforte A, Horban A, Rockstroh JK, Lundgren JD, Mocroft A; EuroSIDA study group. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA. *HIV Med.* 2019 Apr;20(4):264-273. doi: 10.1111/hiv.12711. Epub 2019 Feb 8. PMID: 30734998.
- 7: Zarębska-Michaluk D, Buczyńska I, Simon K, Tudrujek-Zdunek M, Janczewska E,

Dybowska D, Sitko M, Dobracka B, Jaroszewicz J, Pabjan P, Klapaczyński J, Laurans Ł, Mazur W, Socha Ł, Tronina O, Parczewski M, Flisiak R. Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy. *Can J Gastroenterol Hepatol*. 2019 Mar 3;2019:4029541. doi: 10.1155/2019/4029541. PMID: 30941326; PMCID: PMC6420981.

8: Zarębska-Michaluk D, Jaroszewicz J, Buczyńska I, Simon K, Lorenc B, Tudrujek-Zdunek M, Tomasiewicz K, Sitko M, Garlicki A, Janczewska E, Dybowska D, Halota W, Pawłowska M, Pabjan P, Mazur W, Czauż-Andrzejuk A, Berak H, Horban A, Socha Ł, Klapaczyński J, Piekarska A, Blaszkowska M, Belica-Wdowik T, Dobracka B, Tronina O, Deroń Z, Białkowska-Warzecha J, Laurans Ł, Flisiak R. Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4. *J Gastroenterol Hepatol*. 2019 Nov 16. doi: 10.1111/jgh.14936. Epub ahead of print. PMID: 31734959.

9: Lawitz E, Gane E, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich E, Katchman H, Tomasiewicz K, Lahser F, Jackson B, Shaughnessy M, Klopfer S, Yeh WW, Robertson MN, Hanna GJ, Barr E, Platt HL; C-BREEZE-2 Study Investigators. Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. *J Viral Hepat*. 2019 Sep;26(9):1127-1138. doi: 10.1111/jvh.13132. Epub 2019 Jul 11. PMID: 31108015.

10: Flisiak R, Zarębska-Michaluk D. Perspectives of hepatitis C virus (HCV) elimination in Poland. *Clin Exp Hepatol*. 2019 Sep;5(3):210-214. doi: 10.5114/ceh.2019.87633. Epub 2019 Sep 5. PMID: 31598557; PMCID: PMC6781820.

11: Gruszevska E, Cylwik B, Gudowska M, Panasiuk A, Flisiak R, Chrostek L. The concentration of total sialic acid in chronic hepatitis B and C. *Ann Clin Biochem*. 2019 Jan;56(1):118-122. doi: 10.1177/0004563218792292. Epub 2018 Aug 16. PMID: 30027776.

12: Rogalski P, Rogalska-Plonska M, Wroblewski E, Kostecka-Roslen I, Dabrowska M, Swidnicka-Siergiejko A, Wasielica-Berger J, Cydzik M, Hirnle T, Flisiak R, Dabrowski A. Laboratory evidence for hypercoagulability in cirrhotic patients with history of variceal bleeding. *Thromb Res*. 2019 Jun;178:41-46. doi: 10.1016/j.thromres.2019.03.021. Epub 2019 Apr 1. PMID: 30959281.

13: Lawitz E, Flisiak R, Abunimeh M, Sise ME, Park JY, Kaskas M, Bruchfeld A, Wörns MA, Aglitti A, Zamor PJ, Xue Z, Schnell G, Jalundhwala YJ, Porcalla A, Mensa FJ, Persico M. Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. *Liver Int*. 2020 May;40(5):1032-1041. doi: 10.1111/liv.14320. Epub 2019 Dec 26. PMID: 31821716.

14: Rogalski P, Rogalska-Plonska M, Wroblewski E, Kostecka-Roslen I, Dabrowska M, Swidnicka-Siergiejko A, Wasielica-Berger J, Cydzik M, Hirnle T, Dobrzycki S, Flisiak R, Dabrowski A. Blood platelet function abnormalities in cirrhotic patients with esophageal varices in relation to the variceal bleeding history.

Scand J Gastroenterol. 2019 Mar;54(3):311-318. doi: 10.1080/00365521.2019.1578822. Epub 2019 Mar 23. PMID: 30907172.

15: Ahn SH, Marcellin P, Ma X, Caruntu FA, Tak WY, Elkhatab M, Chuang WL, Tabak F, Mehta R, Petersen J, Guyer W, Jump B, Chan A, Subramanian M, Crans G, Fung S, Buti M, Gaeta GB, Hui AJ, Papatheodoridis G, Flisiak R, Chan HLY. Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis. Dig Dis Sci. 2019 Jan;64(1):285-286. doi: 10.1007/s10620-018-5294-y. Erratum for: Dig Dis Sci. 2018 Dec;63(12):3487-3497. PMID: 30324553; PMCID: PMC6830034.

16: Parfieniuk-Kowerda A, Świdorska M, Rogalska M, Maciaszek M, Jaroszewicz J, Flisiak R. Chronic hepatitis B virus infection is associated with decreased serum 25(OH)D concentration in non-cirrhotic patients. Clin Exp Hepatol. 2019 Mar;5(1):75-80. doi: 10.5114/ceh.2019.83160. Epub 2019 Feb 20. PMID: 30915410; PMCID: PMC6431090.

17: Ferenci P, Bourgeois S, Buggisch P, Norris S, Curescu M, Larrey D, Marra F, Kleine H, Dorr P, Charafeddine M, Crown E, Bondin M, Back D, Flisiak R. Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. J Viral Hepat. 2019 Jun;26(6):685-696. doi: 10.1111/jvh.13080. Epub 2019 Mar 5. PMID: 30739368; PMCID: PMC6849558.

18: Simon KA, Flisiak R, Łapiński TW, Janczewska E, Wawrzynowicz-Syczewska M, Jaroszewicz J, Zarębska-Michaluk D, Nazzal K, Bolewska B, Białkowska J, Berak H, Fleischer-Stępniewska K, Tomasiewicz K, Karwowska K, Rostkowska KA, Piekarska A, Tronina O, Madej G, Garlicki A, Łucejko M, Pisula A, Karpińska E, Kryczka W, Wiercińska-Drapała A, Mozer-Lisewska I, Jabłkowski MS, Horban A, Knysz B, Tudrujek M, Halota W. Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C - a real-world study. Clin Exp Hepatol. 2019 Sep;5(3):215-223. doi: 10.5114/ceh.2019.87634. Epub 2019 Sep 5. PMID: 31598558; PMCID: PMC6781817.

19: Łucejko M, Tomasiewicz K, Olczak A, Tudrujek-Zdunek M, Halota W, Jelski W, Donica H, Krintus M, Mroczko B, Flisiak R. Hepatitis C virus core antigen as a possible alternative for evaluation of treatment effectiveness after treatment with direct-acting antivirals. Br J Biomed Sci. 2019 Oct;76(4):190-194. doi: 10.1080/09674845.2019.1654790. Epub 2019 Sep 6. PMID: 31401936.

20: Piekarska A, Jabłonowska E, Garlicki A, Sitko M, Mazur W, Jaroszewicz J, Czauz-Andrzejuk A, Buczyńska I, Simon K, Lorenc B, Dybowska D, Halota W, Pawłowska M, Dobracka B, Berak H, Horban A, Tudrujek-Zdunek M, Tomasiewicz K, Janczewska E, Socha Ł, Laurans Ł, Parczewski M, Zarębska-Michaluk D, Pabjan P, Belica-Wdowik T, Baka-Ćwierz B, Deroń Z, Krygier R, Klapaczyński J, Citko J, Berkan-Kawińska A, Flisiak R. Real life results of direct acting antiviral therapy for HCV infection in HIV-HCV-coinfected patients: Epi-Ter2 study. AIDS Care. 2020 Jun;32(6):762-769. doi: 10.1080/09540121.2019.1645808. Epub 2019 Jul

25. PMID: 31345052.

21: Zarebska-Michaluk D, Piekarska A, Jaroszewicz J, Klapaczyński J, Mazur W, Krygier R, Belica-Wdowik T, Baka-Ćwierz B, Janczewska E, Pabjan P, Dobracka B, Lorenc B, Tudrujek-Zdunek M, Tomasiewicz K, Sitko M, Garlicki A, Czauż-Andrzejuk A, Citko J, Dybowska D, Halota W, Pawłowska M, Laurans Ł, Deroń Z, Buczyńska I, Simon K, Białkowska J, Tronina O, Flisiak R. Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. *Adv Med Sci.* 2020 Mar;65(1):12-17. doi: 10.1016/j.advms.2019.09.002. Epub 2019 Dec 13. PMID: 31841821.

22: Łapiński TW, Łapińska M. Nutritional status in patients with liver cirrhosis. *Clin Exp HEPATOL* 2019; 5, 1: 30–34 DOI: <https://doi.org/10.5114/ceh.2019.83154>
MNiSW – 20